AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 182 min read$CSTL

MAETZOLD DEREK J sold $184K of CSTL (indirect holdings)

MAETZOLD DEREK J (Pres. & Chief Exec. Officer) sold 6,132 indirectly-held shares of CASTLE BIOSCIENCES INC (CSTL) at $30.02 ($0.18M total) across 6 trades on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAETZOLD DEREK J
Published Aug 18, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Neutral
medium confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider confidence, but the 10b5-1 designation generally limits the informational content.

02

Market read

A disclosed insider sale of $184k in CSTL, dated 2026-08-14 and filed 2026-08-18, is likely a low-signal event for trading.

03

What to watch

Indirect ownership and multiple small lots across the same day can make the transaction less informative than a single large discretionary sale.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

The article is a SEC Form 4 insider transaction disclosure for CASTLE BIOSCIENCES, reported by the CEO via an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$CSTLNeutralMedium confidence
Context

CASTLE BIOSCIENCES CEO Maetzold sold $184,082 of CSTL via an open-market sale under a 10b5-1 plan on 2026-08-14.

Expected impact

Low near-term impact; any move is likely sentiment-driven and should fade unless accompanied by other news.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arranged plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Sector

No sector-wide read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be purely liquidity/tax-driven under a 10b5-1 plan, implying no bearish fundamental change.

Key entities

  • issuer
    CASTLE BIOSCIENCES INC

    Subject of the Form 4 insider transaction disclosure.

  • insider
    MAETZOLD DEREK J

    Pres. and Chief Exec. Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min